Integrated Short-Term Palliative Rehabilitation in Incurable Cancer (INSPIRE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05984797 |
Recruitment Status :
Not yet recruiting
First Posted : August 9, 2023
Last Update Posted : August 9, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer | Other: Integrated Short-term Palliative Rehabilitation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 340 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Multinational, parallel group, randomised, controlled, assessor blind, superiority trial |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Owing to the nature of the intervention, it is not possible to blind participants or intervention practitioners. Individual participants are allocated on a 1:1 basis to receive either palliative rehabilitation plus usual care or usual care. Treatment allocation will not be disclosed to the CTRU KCTU trial team or to other members of the research teams involved in data analysis to maintain blinding during outcome assessment and to minimise possible bias. Individual participants are allocated on a 1:1 basis to receive either palliative rehabilitation plus usual care or usual care. A computer-generated minimisation programme that incorporates a random element will be used to ensure that treatment groups are well balanced for: trial country ,baseline FACT-G score (<=64, 65-79, 80+), ECOG performance status (2, 3) in order to guard against chance bias in patient allocation for prognostic factors. |
Primary Purpose: | Supportive Care |
Official Title: | Integrated Short-term Palliative Rehabilitation to Improve Quality of Life and Equitable Care Access in Incurable Cancer: A Multi-national Randomised Controlled Trial |
Estimated Study Start Date : | October 3, 2023 |
Estimated Primary Completion Date : | October 2, 2025 |
Estimated Study Completion Date : | August 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: intervention arm
Integrated Short-term Palliative Rehabilitation + usual care
|
Other: Integrated Short-term Palliative Rehabilitation
Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,). Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians. |
No Intervention: control arm
usual care
|
- Health related quality of life [ Time Frame: Assessed at 8 weeks after enrollment to the study ]Assessed using Functional Assessment of Cancer Therapy (FACT-G) General scale, where high score indicates better functional well-being and quality of life for cancer patients. Lower scores may indicate a greater burden of symptoms, reduced ability to perform daily activities, and overall lower satisfaction with life during the cancer journey.
- FACT-G: Assessed using Functional Assessment of Cancer Therapy - General [ Time Frame: Assessed at 4 and 16 weeks after enrollment to the study ]Functional Assessment of Cancer Therapy (FACT) General scale at 4 and 16 weeks, where high score indicates better functional well-being and quality of life for cancer patients. Lower scores may indicate a greater burden of symptoms, reduced ability to perform daily activities, and overall lower satisfaction with life during the cancer journey.
- Disability - World Health Organization Disability Assessment Schedule (WHODAS 2.0) [ Time Frame: Assessed at 8 and 16 weeks after enrollment to the study ]Higher scores reflect more significant disability, while lower scores indicate better functional status and less disability. It is used to measure and assess the impact of health conditions or disabilities on a participant's ability to function in their daily life.
- Symptoms - Palliative Outcomes Scale [ Time Frame: Assessed at 8 and 16 weeks after enrollment to the study ]Symptoms- Palliative Outcomes Scale - Symptoms (POS-S): designed to evaluate the severity and impact of various symptoms on the participant's quality of life. Higher scores indicate more severe symptoms and a greater impact on the patient's well-being, while lower scores indicate milder symptoms and less disruption in daily life.
- Goal attainment- Goal attainment scale (GAS-Light) [ Time Frame: Assessed at 8 and 16 weeks after enrollment to the study ]Goal attainment- Goal attainment scale (GAS-Light): is a tool used to measure the extent to which an participant has achieved specific goals or objectives.
- Client Service Receipt Inventory [ Time Frame: Assessed at 8 and 16 weeks after enrollment to the study ]Client Service Receipt Inventory at 8 and 16 weeks
- Acceptability - Acceptability of Intervention Measure (AIM) and bespoke questionnaire. *Participants randomised to the intervention arm only [ Time Frame: Assessed within first 2 weeks and then at week 8 after enrollment to the study ]Acceptability of Intervention Measure (AIM) is a 4-item scale that measures the perception of satisfaction and agreeability of an intervention. Items are rated using a Likert-type semantic differential scale, ranging from 1 to 5. The AIM has a Cronbach's alpha of 0.85
- Appropriateness - Intervention Appropriateness Measure (IAM) and bespoke questionnaire. *Participants randomised to the intervention arm only [ Time Frame: Assessed within first 2 weeks and then at week 8 after enrollment to the study ]The Intervention Appropriateness Measure (IAM), a 4-item scale measuring the perceived relevance and compatibility of the intervention. Items are rated using a Likert-type semantic differential scale, ranging from 1 to 5. The IAM has a Cronbach's alpha of 0.91
- Access - semi-structured qualitative interviews [ Time Frame: Participants will be interviewed in their own language by a researcher at the inclusion site after completing the rehabilitations intervention and their consent obtained ]Qualitative interviews will be conducted to assess the acceptability and the appropriateness of the intervention from the patients' point of view. These will allow patients to offer their opinion and feelings about the intervention, to identify convergences and divergences between the quantitative and qualitative parts, and finally to deepen our implementation evaluation of the acceptability and appropriateness aspects.
- Bespoke Questionnaire. *Participants randomised to the intervention arm only [ Time Frame: Assessed within first 2 weeks and then at week 8 after enrollment to the study ]A bespoke quantitative questionnaire was designed using adapted items from our literature review of published implementation questionnaires (https://implementationoutcomerepository.org/), rated based on a semantic differential scale (Likert-type), to fit with the ratings used for AIM and IAM
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged 18 years or older.
- Diagnosis of incurable solid cancer: lung, colorectal, breast, prostate or other, irrespective of timing in relation to any oncology or palliative care treatments
- Eastern Cooperative Oncology Group performance status 2-3
- Able to provide informed consent and complete trial assessments in available languages.
Exclusion Criteria:
- Blood cancers: Leukaemia, Lymphoma, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder (MPD), Multiple Myeloma.
- Currently receiving specialist rehabilitation* for their cancer or co-morbidity-related dysfunction, or received within the two weeks prior to consent.
- Clinician rated prognosis of less than 3 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05984797
Contact: INSPIRE Research Team | 02078480532 | INSPIRE@kcl.ac.uk |
United Kingdom | |
Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London | |
London, United Kingdom, SE5 9PJ | |
Contact: Matthew Maddocks matthew.maddocks@kcl.ac.uk |
Principal Investigator: | Matthew Maddocks | KCL |
Responsible Party: | King's College London |
ClinicalTrials.gov Identifier: | NCT05984797 |
Other Study ID Numbers: |
INSPIRE 328722 ( Other Identifier: IRAS ) |
First Posted: | August 9, 2023 Key Record Dates |
Last Update Posted: | August 9, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
cancer Rehabilitation palliative support disability |